DALLAS: GlaxoSmithKline is partnering with a San Diego research institute to study brain function and treatments to potentially reverse or slow down neurodegeneration.
The Sanford Burnham Prebys Medical Discovery Institute in La Jolla and GlaxoSmithKline, which has operations in the Philadelphia area, will create a center on Sanford Burnham’s campus with the goal of finding new medicines for diseases such as Alzheimer’s and other forms of dementia.
Under a three-year agreement, GSK will fund a research laboratory where scientists and staff from Sanford Burnham will work with GSK neuroscientists. Financial terms were not disclosed.
“Neurogenerative diseases cross many fields of science, and this partnership takes full advantage of the depth and breadth in expertise” of both organizations, said Min Li, Glaxo’s senior vice president and global head of neurosciences.
People worldwide living with dementia is set to triple to 135 million by 2050, yet there are currently no medicines that can prevent or cure the disorder, the two groups said…